Compound index

Small-Molecule Drugs

Apomorphine

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Evidence status & limitations

FDA-approved Parkinson’s disease products do not establish FDA approval for sexual-health indications.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Apokyn · Parkinson’s Disease

    Acute intermittent treatment of hypomobility or off episodes associated with advanced Parkinson’s disease.

    Authoritative label record
  • Onapgo · Parkinson’s Disease

    Treatment of motor fluctuations in adults with advanced Parkinson’s disease. This is a separate product-specific indication from Apokyn.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Known risks & open questions

Nausea, hypotension, somnolence and impulse-control effects are documented concerns.

Key sources

Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

Related compounds

  • Finasteride

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Metformin

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Methylthioninium chloride

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Minoxidil

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Omeprazole

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

Related glossary terms